Journal of the American Medical Association (JAMA) looks at genetic tests
This article was originally published in Clinica
A simple diagnostic test for hereditary breast and ovarian cancer is possible but more data on sensitivity and specificity are needed, according to a paper in JAMA (February 15th). The paper is supported by a guide to assessment and counselling for clinicians.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.